Published
2024-10-10
Section
Articles
How to Cite
恶性肺结节诊疗中免疫组化的应用
黄 春暖
右江民族医学院
张 九进
右江民族医学院附属玉林医院
DOI: https://doi.org/10.59429/xjjz.v6i3.7282
Keywords: 肺结节；肺癌；免疫组化；TTF-1；Napsin A；CK7；p63；p40；CK5/6；Syn；CgA；CD56；Ki-67
Abstract
随着医疗水平的提高和 CT 技术的普遍，偶发性肺结节被发现的概率不断提高，恶性结节占比不容小觑。 免疫组化的出现，通过获取有关肿瘤的生物学特征、免疫环境和治疗靶点的信息，其与影像特点、肺癌 TNM 分型及 临床病理分型等结合，进而更好指导临床上的治疗以及预测肺癌患者的预后。
References
[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA: A Cancer Journal for Clinicians,2021,71(3):209-249.
[2] 赵珂嘉,刘成武,刘伦旭.《IASLC 第九版肺癌TNM分期》解读[J].中国胸心血管外科临床杂志,2024,31(4):489-497.
[3] BADE B C, DELA CRUZ C S. Lung Cancer 2020[J]. Clinics in Chest Medicine,2020,41(1):1-24.
[4] A G S J, AND DAVID R BALDWIN B C. Recent advances in the management of lung cancer[J]. Clinical Medicine,2018,18(2):41-46.
[5] NICHOLSON A G, TSAO M S, BEASLEY M B, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015[J]. Journal of Thoracic Oncology,2022,17(3):362-387.
[6] 雷光焰,张艰,闫小龙.肺结节诊治西北地区专家共识(2021年版)[J].中国医药科学,2021,11(23):16-22.
[7] 曹文军,薛洪省,汤敏,等.良性肺结节的临床特点及其诊断和治疗[J].中华胸部外科电子杂志,2020,7(1):22-29.
[8] YU L, ZHANG B, ZOU H, et al. Multivariate Analysis on Development of Lung Adenocarcinoma Lesion from Solitary Pulmonary Nodule[J]. Contrast Media & Molecular Imaging,2022:1-5.
[9] PETER J. MAZZONE M M, LOUIS LAM M. Evaluating the Patient With a Pulmonary Nodule A Review[J]. JAMA, 2021,327(3):264-273.
[10] WANG Y, HUANG Q, LI J. Analysis of Clinical and Pathological Features of Malignant Pulmonary Nodules[J]. Alternative therapies in health and medicine,2023,29(4):188-193.
[11] LIU C, ZHAO L, WU F, et al. The multidisciplinary team plays an important role in the prediction of small solitary pulmonary nodules: a propensity-score-matching study[J]. Annals of Translational Medicine,2019,7(23):740.
[12] HOU H, YU S, XU Z, et al. Prediction of malignancy for solitary pulmonary nodules based on imaging, clinical characteristics and tumor marker levels[J]. European Journal of Cancer Prevention,2021,30(5):382-388. [13] ZHANG L, WAN R, CHEN J, et al. Analysis of the correlation between clinical and imaging features of malignant lung nodules and pathological types[J]. Frontiers in Surgery,2023(10).
[14] RAMI-PORTA R, NISHIMURA K K, GIROUX D J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer[J]. Journal of Thoracic Oncology,2024,19(7):1007-1027.
[15] KIM H, GOO J M, KIM Y T, et al. Validation of the Eighth Edition Clinical T Categorization System for Clinical Stage IA, Resected Lung Adenocarcinomas: Prognostic Implications of the Ground-Glass Opacity Component[J]. Journal of thoracic oncology,2020,15(4):580-588.
[16] HUANG J O R G D, MEMBERS OF THE STAGING AND PROGNOSTIC FACTORS COMMITTEE M O T A. The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer[J]. Journal of thoracic oncology,2024,19(5):766-785.
[17] FONG KM R A G D, MEMBERS OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER STAGING AND PROGNOSTIC FACTORS COMMITTEE M O T A. The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer[J]. Journal of thoracic oncology,2024,19(5):786-802.
[18] DOVE A P H, RYCKMAN J, CHHABRA A, et al. American Society of Clinical Oncology 2022 Annual Meeting Highlights for Radiation Oncologists[J]. Advances in Radiation Oncology,2023,8(1):101107.
[19] LIAO Y, YANG F, LI X, et al. The Prognostic Value of TTF-1/NKX2-1 in Lung Squamous Cell Carcinoma[J]. Appl Immunohistochem Mol Morphol,2023,31(6):414-420.
[20] 李小利.TTF-1和Ki-67在小细胞肺癌中的表达及对EP化疗方案疗效及预后的预测价值[D].蚌埠:蚌埠医学院,2023.
[21] NIKOLAJ FROST T Z M V, CHRISTOPH RUWWEGLÖSENKAMP M R M B, OCHSENREITHER B T N S, et al. Pemetrexed-based chemotherapy is inferior to pemetrexedfree[J].2020,21(6):607-621.
[22] WU J, ZHANG Y, DING T, et al. Napsin A Expression in Subtypes of Thyroid Tumors: Comparison with Lung Adenocarcinomas[J]. Endocrine Pathology,2020,31(1):39-45.
[23] BULUTAY P, AKYUREK N, MEMIS L. Clinicopathological and Prognostic Significance of the EML4-ALK Translocation and IGFR1, TTF1, Napsin A Expression in Patients with Lung Adenocarcinoma[J]. Turkish Journal of Pathology,2020,37(1):7-17.
[24] ZHANG P, HAN Y P, HUANG L, et al. Value of napsin A and thyroid transcription factor-1 in the identification of primary lung adenocarcinoma[J]. Oncol Lett,2010,1(5):899-903.
[25] 梁进萍.Napsin A、TTF-1、CK7与肺腺癌EGFR基因突变状态相关性研究[D].乌鲁木齐:新疆医科大学第一临床医学院,2021.
[26] ALABDULLAH B, HADJI-ASHRAFY A. Identification of the most specific markers to differentiate primary pulmonary carcinoma from metastatic gastrointestinal carcinoma to the lung[J]. Diagnostic Pathology,2022,17(1).
[27] TONG L, XU H. Cytokeratin 7 and thyroid transcription factor - 1 levels in patients with lung cancer complicated with superior vena cava syndrome and their correlation with clinicopathological characteristics[J]. J BUON,2019,24(6):2294-2302.
[28] MA Y, FAN M, DAI L, et al. The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment[J]. Tumor Biology,2015,36(10):8085-8092.
[29] FAN J, LI H, ZHOU C, et al. Classifying Pulmonary and Urinary High-grade Neuroendocrine Carcinoma by CK7 Immunohistochemistry[J]. Appl Immunohistochem Mol Morphol,2022,30(6):459-468.
[30] LILO M T, ALLISON D, WANG Y, et al. Expression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitations[J]. Journal of the American Society of Cytopathology,2016,5(3):123-132.
[31] WANG J, WANG X, XU X, et al. Expression and Significance of CK5/6, P63, P40, CK7, TTF-1, NapsinA, CD56, Syn and CgA in Biopsy Specimen of Squamous Cell Carcinoma, Adenocarcinoma and Small Cell Lung Carcinoma[J]. International journal of morphology,2020,38(2):247-251.
[32] IWANO S, KAMIYA S, ITO R, et al. Iodine-related attenuation in contrast-enhanced dual-energy computed tomography in smallsized solid-type lung cancers is associated with the postoperative prognosis[J]. Cancer Imaging,2021,21(1).
[33] TIAN S, JIANGUO X, TIAN W, et al. Application of dualenergy computed tomography in preoperative evaluation of Ki-67 expression levels in solid non-small cell lung cancer[J]. Medicine,2022,101(31):29444.
[34] 乔鸿飞,马文杰,贾明选,等.恶性孤立性肺结节患者电视胸腔镜手术治疗的预后情况及其影响因素分析[J].临床医学工程,2023,30(10):1471-1472.
[35] LI G, HUANG R, ZHU M, et al. Native T1-mapping and diffusionweighted imaging (DWI) can be used to identify lung cancer pathological types and their correlation with Ki-67 expression[J]. Journal of Thoracic Disease,2022,14(2):443-454.